DAIC

FEBRUARY 23, 2024

milla1cf Fri, 02/23/2024 - 11:54 February 23, 2024 — Cleerly , the company creating a new standard of care to aid in the diagnosis of heart disease, announced that its recently U.S. Prior studies have demonstrated the independent and incremental benefit of Cleerly ISCHEMIA applied to CCTA beyond traditional assessment.

Ischemia 105

Ischemia Coronary Artery Disease Physiology Cardiovascular Imaging 105

DAIC

MAY 14, 2024

Together, the two companies will work to further the development and commercialization of Medis Quantitative Flow Ratio (Medis QFR), a non-invasive approach to the assessment of coronary physiology, as part of GE HealthCare’s interventional cardiology portfolio built around the Allia Platform.

Coronary Artery Disease 111

Coronary Artery Disease Interventional Cardiology Innovation Physiology 111

DAIC

FEBRUARY 13, 2024

Cleerly, a digital healthcare company focused on heart disease, has announced continued strong scientific evidence supporting the clinical utility of its products, detailing a study published online on Jan. 25, 2024 in the European Heart Journal Cardiovascular Imaging. In Press European Heart Journal CV Imag 2024.This

Coronary Artery Disease 103

Coronary Artery Disease Ischemia Atherosclerosis Cardiovascular Imaging 103

DAIC

MARCH 28, 2024

milla1cf Thu, 03/28/2024 - 07:00 March 28, 2024 — Cleerly , the company on a mission to create a new standard of care to aid in the diagnosis of heart disease, shared findings from a study published online in the Journal of the American College of Cardiology: Cardiovascular Imaging on March 13, 2024. JACC Cardiovasc Imaging.

Ischemia 110

Ischemia Atherosclerosis Coronary Artery Disease Chest Pain 110